Louis Larrouquere

Dr. Louis Larrouquere

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2020 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LLLouis Larrouquere
Louis Larrouquere
MGManon Gabin
Manon Gabin
EPEmmanuelle Poingt
Emmanuelle Poingt
AMAmelle Mouffak
Amelle Mouffak
AHAlex Hlavaty
Alex Hlavaty
HTHôpital Bretonneau The Société Française de Pharmacologie Et de Thérapeutique
Hôpital Bretonneau The Société Française de Pharmacologie Et de Thérapeutique

10 January 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ABAxel de Bernardi
Axel de Bernardi
TBThomas Bachelot
Thomas Bachelot
LLLouis Larrouquere
Louis Larrouquere
The incidence of leptomeningeal metastases (LM) is increasing among breast cancer patients, but their prognosis remains dismal. Many therapeutic options are now available to treat HER2-positive (HER2+) metastatic breast cancer (MBC) involving the central nervous system (CNS). This case report illustrates a long-lasting response of more than 2 years in a patient with HER2+ MBC with LM after sequential administration of systemic and intrathecal (IT) anti-HER2 therapies and highlights that an appropriate treatment of HER2+ LM can result in durable survival.

Verified
Journal Article
Open access
PDF file
LLLouis Larrouquere
Louis Larrouquere
SBSylvie Berthier
Sylvie Berthier
BCBenoit Chovelon
Benoit Chovelon
CGCatherine Garrel
Catherine Garrel
VVVéronique Vacchina
Véronique Vacchina
FPFlorence PUCH
Florence PUCH
Glioblastoma (GBM) is the most aggressive malignant glioma, with a very poor prognosis; as such, efforts to explore new treatments and GBM’s etiology are a priority. We previously described human GBM cells (R2J-GS) as exhibiting the properties of cancer stem cells (growing in serum-free medium and proliferating into nude mice when orthotopically grafted). Sodium selenite (SS)—an in vitro attractive agent for cancer therapy against GBM—was evaluated in R2J-GS cells. To go further, we launched a preclinical study: SS was given orally, in an escalation-dose study (2.25 to 10.125 mg/kg/day, 5 days on, 2 days off, and 5 days on), to evaluate (1) the absorption of selenium in plasma and organs (brain, kidney, liver, and lung) and (2) the SS toxicity. A 6.75 mg/kg SS dose was chosen to perform a tumor regression assay, followed by MRI, in R2J-GS cells orthotopically implanted in nude mice, as this dose was nontoxic and increased brain selenium concentration. A group receiving TMZ (5 mg/kg) was led in parallel. Although not reaching statistical significance, the group of mice treated with SS showed a slower tumor growth vs. the control group (p = 0.08). No difference was observed between the TMZ and control groups. We provide new insights of the mechanisms of SS and its possible use in chemotherapy.

28 May 2025 in Bulletin du Cancer
Verified
Journal Article
Open access
LLLouis Larrouquere
Louis Larrouquere
ECEmilie Clement
Emilie Clement
MSMarie Pierre Sunyach
Marie Pierre Sunyach
ABAxel De Bernardi
Axel De Bernardi
ECErika Cosset
Erika Cosset
TBThomas Bachelot
Thomas Bachelot
Leptomeningeal disease (LMD) from breast cancer is defined by the invasion of the leptomeninges and cerebrospinal fluid (CSF) by tumor cells. Historically associated with a very poor prognosis and survival measured in weeks, their management has evolved considerably. Therapeutic advances, such as the introduction of targeted therapies, and a better understanding of the pathophysiology of LMD now enable earlier diagnosis through dedicated MRI sequences and optimized CSF analysis. The EANO-ESMO classification notably distinguishes type I LMD (cytology-positive), which carries a worse prognosis but is more sensitive to intrathecal (IT) treatments, from type II LMD (negative or uncertain cytology), often more responsive to local-regional approaches like radiotherapy. Data from large retrospective cohorts highlight the importance of combination therapies: systemic treatments, IT injections, radiotherapy, as well as early symptomatic and palliative care. This multidisciplinary approach improves median survival, now reaching several months, and can even surpass 10 months in HER2+ cases. Innovative clinical trials, such as ETIC-LM (NCT05800275) - a French phase II study evaluating the combination of IT trastuzumab, oral tucatinib, and oral capecitabine offer encouraging new strategies for patient care. Although the prognosis remains poor, recent advancements suggest a more hopeful future, providing better disease control and improved quality of life for patients with LMD from breast cancer.

6 January 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
AMAurelien Maureille
Aurelien Maureille
EVEnora Vauleon
Enora Vauleon
DMDavid Meyronet
David Meyronet
CFCécile Faure
Cécile Faure
ABAlexandre Basle
Alexandre Basle
PLPierre LEBLOND
Pierre LEBLOND
Background: The prognosis of adult patients with recurrent malignant embryonal brain tumors remains poor due to the lack of effective and validated treatment. A metronomic and antiangiogenic chemotherapy regimen called MEMMAT was developed in children, with promising results. Additional data on feasibility, tolerance, and efficacy in adults are necessary. Methods: This retrospective observational case series included adult patients with relapsing medulloblastoma (MB) or pineoblastoma (PB) treated with MEMMAT-adapted protocol. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and personalized intraventricular chemotherapy. Results: Four SHH-activated MB and 2 PB were included. Median duration of treatment was 12 months (range 3–21). Significant partial response occurred in 2/4 MB patients and 2/2 PB. The best responses were observed on leptomeningeal lesions. Main grade 3–4 toxicity was neutropenia in all patients (no febrile neutropenia) and lymphopenia in all but one (2 opportunistic infections). Dose adjustments in chemotherapy and thalidomide for hematotoxicity were necessary in all patients within the first 3 months. Cumulative neurotoxicity from thalidomide affected the 4 patients with prolonged treatment (1 grade 3, 3 grade 2). Rechallenge was tried in PB patients and successful (duration: 9 months). Conclusions: MEMMAT is feasible in adult patients and can lead to a significant and sustained response in recurrent malignant embryonal brain tumors. Hematotoxicity is progressive and manageable. The withdrawal of thalidomide and starting dose adjustments on chemotherapy might be discussed.

1 January 2024 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
LLLouis Larrouquere
Louis Larrouquere
CDChristelle Dufour
Christelle Dufour
CFCécile Faure-Conter
Cécile Faure-Conter
CAClaire Alapetite
Claire Alapetite
DMDavid Meyronet
David Meyronet
DFDidier Frappaz
Didier Frappaz
Background: High-risk medulloblastoma (HRMB) is rare in adults. The 5-year overall survival rate is less than 60%. We present here a retrospective analysis of adults treated with an intensive pediatric chemo-radiotherapy regimen PNET HR + 5: NCT00936156. Methods: Eighteen patients over the age of 20 (range, 20–33 years) with HRMB (n = 13), pinealoblastoma (n = 4), and central nervous system embryonal tumor (n = 1) were treated with 2 courses of carboplatin-etoposide followed by 2 courses of high-dose thiotepa (HDT) with autologous hematopoietic stem-cell rescue. A craniospinal irradiation (CSI; 36 Gy craniospinal axis then a boost of 18 Gy to the primary tumor site) was then initiated within 150 days of surgery, completed with 6 cycles of temozolomide; the axis irradiation was not mandatory for non-metastatic pinealoblastoma. Results: We observed no progression under chemotherapy and no toxic death. Four patients received only 1 HDT. Two non-metastatic pinaloblastomas received only focal irradiation. One medulloblastoma received only 25 Gy on the axis. 56% (10/18) received 6 cycles of temozolomide. No long-term toxicity was recorded. The median time between surgery and CSI was 175 days (range, 115–250). With a median follow-up of 6.0 years (range, 2.6–9), the progression-free survival and overall survival rates for medulloblastoma were respectively 65% (95% CI: 31%–86%) and 76% (95% CI: 42%–91%) at 5 years. Conclusions: The PNET HR + 5 regimen showed promising results in an adult population, with a meaningful improvement in progression-free survival and overall survival in patients with HRMB.